A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.
News & Analysis: Biohaven Pharmaceutical Holding Company Ltd.
The drug enters a crowded market -- but it has a convenient format.
Biohaven’s shares dropped after a failed clinical trial, and risk-tolerant investors are snapping them up.
The company's candidate troriluzole failed to meet its primary endpoint in a trial as a treatment for generalized anxiety disorder.
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.
Historically, the underlying cause of ALS has evaded researchers, except in rare genetic cases. But more light has been shone on the disease and the potential of new avenues for drug intervention.
Why Blue Apron Holdings, Biohaven Pharmaceutical Holding, and GCP Applied Technologies Slumped Today
These stocks missed out on a big Wall Street rally.
Dilution is coming for shareholders, while an acquisition doesn't seem as likely.
Rumor has it that the drugmaker is up for sale.